Susceptibility of the developing brain to acute hypoglycemia involving A1 adenosine receptor activation

Mina Kim1, Zhao-Xue Yu, Bertil B Fredholm

  • 1Section of Developmental Endocrinology and Biology, Yale Child Health Research Center, New Haven, CT 06520, USA.

Insights

The developing brain is vulnerable to hypoglycemia, with adenosine A(1) receptor activation contributing to injury in immature mice. This study clarifies the sensitivity of the developing nervous system to low blood sugar and its underlying mechanisms.

Area of Science:

  • Neuroscience
  • Developmental Biology
  • Endocrinology

Background:

  • The developing brain's vulnerability to hypoglycemia is debated.
  • The specific conditions causing hypoglycemic brain injury during development are unclear.

Purpose of the Study:

  • To investigate the developing brain's sensitivity to acute hypoglycemia.
  • To determine the role of adenosine A(1) receptors (A(1)AR) in hypoglycemic brain injury during development.

Main Methods:

  • Established an in vivo model of insulin-induced hypoglycemia in mice.
  • Utilized TUNEL labeling to assess neuronal degeneration in the hippocampus and striatum.
  • Conducted in vitro studies using hippocampal slice cultures from mice at different developmental stages.
  • Examined the effects of adenosine A(1) receptor (A(1)AR) antagonists and agonists on hypoglycemic damage.
  • Assessed hypoglycemic injury in A(1)AR knockout mice.

Main Results:

  • Hypoglycemic brain injury was observed in P7 mice after 4 hours, with greater injury at P7 than P21.
  • Immature hippocampal slices (P3 and P7) showed more neuronal injury than older slices (P14 and P21).
  • A(1)AR antagonism reduced damage, while agonists exacerbated it, especially in very young pups.
  • A(1)AR knockout mice exhibited significantly reduced hypoglycemic brain injury compared to heterozygous controls.

Conclusions:

  • The developing nervous system is sensitive to acute hypoglycemic injury.
  • Adenosine A(1) receptor activation plays a critical role in exacerbating hypoglycemic brain damage, particularly in the immature brain.

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
Desensitization and Tachyphylaxis01:20

Desensitization and Tachyphylaxis

Tachyphylaxis is described as a rapid decrease in response to a drug after repeated or continuous administration of the same drug dose. It is a phenomenon where the body becomes less responsive to a particular substance or intervention over time, requiring higher doses or stronger interventions to achieve the same effect. It results from adaptive changes in the body's receptors, signaling pathways, or physiological processes that occur in response to prolonged exposure to a stimulus.
Several...
Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Type I Diabetes I: Introduction01:12

Type I Diabetes I: Introduction

Type 1 diabetes mellitus is a chronic metabolic disorder characterized by an absolute deficiency of insulin resulting from the autoimmune destruction of pancreatic β-cells. Although it can occur at any age, it is most commonly diagnosed in childhood, adolescence, or early adulthood. The loss of insulin production impairs cellular glucose uptake, resulting in persistent hyperglycemia and necessitating lifelong insulin therapy.Autoimmune Destruction of β-CellsThe hallmark of type 1 diabetes is an...
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...